EXBIO Antibodies

PRODUCT DATA SHEET

1P-756-T025

Monoclonal Antibody to CD255 / TWEAK Phycoerythrin (PE) conjugated (25 tests)

Clone: CARL-1

Isotype: Mouse IgG3

Specificity: The mouse monoclonal antibody CARL-1 recognizes CD255 / TWEAK, a type II transmembrane protein of the TNF superfamily able to weakly induce apoptosis in many cell types.

Regulatory Status: RUO

Immunogen: human CD255-transfected 2PK-3 cells

Species Reactivity: Human

Preparation: The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.

Storage Buffer: The reagent is provided in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide.

Storage / Stability: Store in the dark at 2-8ºC. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.

Usage: The reagent is designed for Flow Cytometry analysis of human blood cells using 10 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension.
The content of a vial (0.25 ml) is sufficient for 25 tests.

Expiration: See vial label

Lot Number: See vial label

Background: CD255 / TWEAK (TNF-related weak inducer of apoptosis), a type II transmembrane protein expressed as membrane-bound and secreted form, can induce apoptosis in many tissues and cell lines through its receptor CD266 / TWEAK R. On the other hand, in endothelial cells this interaction can induce proliferation and promote angiogenesis including neovascularization of tumours. CD255 can act in a juxtacrine manner to initiate cellular responses, and induces secretion of pro-inflammatory cytokines. Besides CD266, CD255 may also bind to DR3.

For laboratory research only, not for drug, diagnostic or other use.

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic
Tel: +420 261 090 666 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz

References:

*Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H: Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med. 2000 Nov 6;192(9):1373-80.

*Brown SA, Ghosh A, Winkles JA: Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway. J Biol Chem. 2010 Jun 4;285(23):17432-41.

*Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S: TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem. 2003 Sep 19;278(38):36005-12.

*Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T: Proinflammatory effects of tumour necrosis factor-like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts. Clin Exp Immunol. 2006 Dec;146(3):540-9.

*Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H: Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol. 2003 Jan 1;170(1):341-8.

*Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K, Yagita H, Nakajima Y: Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp Ther Med. 2011 Jan;2(1):103-108

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic
Tel: +420 261 090 666 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz